High-Dose Samarium-153 Ethylene Diamine Tetramethylene Phosphonate: Low Toxicity of Skeletal Irradiation in Patients With Osteosarcoma and Bone Metastases

PURPOSE: Samarium-153 ethylene diamine tetramethylene phosphonate (153Sm-EDTMP), a bone-seeking radiopharmaceutical, provides therapeutic irradiation to osteoblastic bone metastases. Because the dose-limiting toxicity of 153Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer. PATIENTS AND METHODS: Patients with locally recurrent or metastatic osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30 mCi/kg of 153Sm-EDTMP. RESULTS: Thirty patients were treated with 153Sm-EDTMP. Transient symptoms of hypocalcemia were seen at 30 mCi/kg. Estimates of radioisotope bound to bone surfaces and marrow radiation dose were linear with injected amount of 153Sm-EDTMP. Cytopenias also occurred in all subjects and were dose-related. At day +13 after 153Sm-EDTMP, residual whole-body radioactivity was 1% to 65% of whole-body radioactivity considered safe for PBPC infusion, 3.6 mCi. After PBPC or marrow infusion on day +14 after 153Sm-EDTMP, recovery of hematopoiesis was problematic in two patients at the 30 mCi/kg dose infused with less than 2 × 106 CD34+/kg on day +14, but not in other patients. Reduction or elimination of opiates for pain was seen in all patients. Patients had no adverse changes in appetite or performance status. CONCLUSION: 153Sm-EDTMP with PBPC support can provide bone-specific therapeutic irradiation (estimates of 39 to 241 Gy). Hematologic toxicity at 30 mCi 153Sm-EDTMP/kg requires PBPC grafts with more than 2 × 106 CD34+/kg to overcome myeloablative effects of skeletal irradiation. Nonhematologic side effects are minimal.

Download Full-text

A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D3in breast cancer patients with bone metastases

Cancer ◽

10.1002/cncr.24749 ◽

2010 ◽

Vol 116 (2) ◽

pp. 284-291 ◽

Cited By ~ 44

Author(s):

Eitan Amir ◽

Christine E. Simmons ◽

Orit C. Freedman ◽

George Dranitsaris ◽

David E. C. Cole ◽

...

Keyword(s):

Breast Cancer ◽

Bone Metastases ◽

Cancer Patients ◽

High Dose ◽

Phase 2 ◽

Breast Cancer Patients ◽

Phase 2 Trial

Download Full-text

Polymorphisms in XRCC1, XRCC3, and CCND1 and Survival After Treatment for Metastatic Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2006.05.9923 ◽

2006 ◽

Vol 24 (36) ◽

pp. 5645-5651 ◽

Cited By ~ 58

Author(s):

Mary A. Bewick ◽

Michael S.C. Conlon ◽

Robert M. Lafrenie

Keyword(s):

Breast Cancer ◽

Cell Cycle ◽

Dna Repair ◽

Metastatic Breast Cancer ◽

Bone Metastases ◽

Cell Cycle Control ◽

Multivariable Analysis ◽

Metastatic Breast ◽

High Dose ◽

Cancer Specific Survival

Purpose Single nucleotide polymorphisms (SNPs) in DNA repair and cell cycle control genes may alter protein function and therefore the efficacy of DNA damaging chemotherapy. We retrospectively evaluated the association of SNPs in DNA repair genes, XRCC1-01 (Arg399Gln) and XRCC3-01 (Thr241Met), and a cell cycle control gene, CCND1-02 (A870G), with progression-free survival (PFS) and breast cancer specific survival (BCSS) in patients with metastatic breast cancer (MBC). Patients and Methods SNPs in 95 patients with MBC enrolled onto one of five prospective clinical trials of high-dose chemotherapy and autologous stem-cell transplantation were evaluated using genotyping assays. Results For XRCC1-01, the hazard ratio (HR) for BCSS was 2.8 (95% CI, 1.60 to 5.00) and the HR for PFS was 2.0 (95%CI, 1.12 to 3.43). For XRCC3-01, the HR for BCSS was 2.0 (95%CI, 1.12 to 3.70) and the HR for PFS was 2.0 (95%CI, 1.09 to 3.59). For CCND1-02, the HR for BCSS was 1.8 (95%CI, 1.12 to 2.78) and the HR for PFS was 1.8 (95%CI, 1.15 to 2.85). Patients carrying one variant genotype (HR, 1.7; 95%CI, 1.07 to 2.82) or combinations of any two variant genotypes (HR, 4.7; 95% CI, 2.41 to 8.94) had significantly poorer BCSS compared with patients carrying zero variants. In multivariable analysis, XRCC1-01, presence of liver metastases, and bone metastases independently predicted BCSS. Combinations of any two variant genotypes were stronger independent predictors of BCSS and PFS than the presence of liver or bone metastases. Conclusion XRCC1-01, XRCC3-01, and CCND1-01 may be predictive of survival outcome in patients with MBC treated with DNA damaging chemotherapy.

Download Full-text

Compatibility of indigenous isolates HR1, HR2 of entomopathogenic nematodes, with low-toxicity insecticides for control of fall armyworm, Spodoptera frugiperda (J.E. Smith) (Lepidoptera: Noctuidae) and tomato leafminer, Tuta absoluta (Meyrick) (Lepidoptera: Gelechiidae)

10.21203/rs.3.rs-1199047/v1 ◽

2022 ◽

Author(s):

Indra Kumar Kasi ◽

Mohinder Singh ◽

Kanchhi Maya Waiba

Keyword(s):

Invasive Species ◽

Spodoptera Frugiperda ◽

Entomopathogenic Nematodes ◽

Fall Armyworm ◽

Steinernema Feltiae ◽

High Dose ◽

Natural Ecosystems ◽

Percent Mortality ◽

Low Toxicity ◽

Lepidoptera Noctuidae

Abstract Invasive species are a major danger to agronomic and natural ecosystems, and due to environmental concerns about pesticide use, EPNs have the potential to replace larvicidal action in pest management. The goal was to see how well local isolates of Steinernema feltiae (HR1) and Heterorhabditis bacteriophora (HR2) controlled invasive species when combined with low-toxicity pesticides. HR1 + Spinosad, chlorantraniliprole produced over 90% mortality in larvae at 96 hours, while HR2 + Spinosad, chlorantraniliprole caused over 95% mortality at 96 hours. After treatment, the high dose was regarded the least hazardous technique for controlling fall armyworm. At the high dose, HR1 + Spinosad, chlorantraniliprole produced larvae death of over 100 percent at 96 hours, and HR2 + Spinosad, chlorantraniliprole caused mortality of over 97.50 percent at 96 hours, and should be considered as a least hazardous strategy for T. absoluta management. Controlling larvae mortality of above 100% at 96 hours in combination with low-toxicity insecticide dosages should be included as a least harmful technique to control T. absoluta. The results showed that these HR2 strains have high pathogenicity against T. absoluta and S. frugiperda and have potential for control in integrated approaches, causing 100 percent and 90.00 percent mortality of T. absoluta and S. frugiperda at 96 hours at the high dose as a least toxic strategy to control.

Download Full-text

Evaluation of a Model-based Dose Calculation Algorithm (Acuros) for Intraosseous High Dose Rate Brachytherapy (HDR) With Intramedullary Nailing for Bone Metastases

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2020.07.698 ◽

2020 ◽

Vol 108 (3) ◽

pp. e292

Author(s):

N. Hassan Rezaeian ◽

B.S. Gannavarapu ◽

M.R. Folkert ◽

R.D. Timmerman ◽

B.A. Hrycushko

Keyword(s):

Bone Metastases ◽

Dose Rate ◽

Intramedullary Nailing ◽

Dose Calculation ◽

High Dose Rate ◽

High Dose ◽

Calculation Algorithm ◽

High Dose Rate Brachytherapy ◽

Dose Calculation Algorithm ◽

Model Based

Download Full-text

Low Toxicity with Continuous Infusion of High-Dose Bleomycin in Poor Prognostic Testicular Cancer

American Journal of Clinical Oncology ◽

10.1097/00000421-199308000-00009 ◽

1993 ◽

Vol 16 (4) ◽

pp. 323-326 ◽

Cited By ~ 12

Author(s):

R. Gerson ◽

E. Tellez Bernal ◽

M. Lazaro Leon ◽

E. Sanchez Forgach ◽

C. Garcia Irigoyen ◽

...

Keyword(s):

Testicular Cancer ◽

Continuous Infusion ◽

High Dose ◽

Low Toxicity

Download Full-text

High-dose single-fraction IMRT versus fractionated external beam radiotherapy for patients with spinal bone metastases: study protocol for a randomized controlled trial

Trials ◽

10.1186/s13063-015-0761-7 ◽

2015 ◽

Vol 16 (1) ◽

Cited By ~ 7

Author(s):

Harald Rief ◽

Sonja Katayama ◽

Thomas Bruckner ◽

Stefan Rieken ◽

Tilman Bostel ◽

...

Keyword(s):

Randomized Controlled Trial ◽

Bone Metastases ◽

Study Protocol ◽

Controlled Trial ◽

External Beam Radiotherapy ◽

High Dose ◽

External Beam ◽

Single Fraction ◽

Randomized Controlled ◽

Spinal Bone Metastases

Download Full-text

Endoluminal High-Dose-Rate Brachytherapy with a Palliative aim in Esophageal Cancer: Preliminary Results at the Institut Gustave Roussy

Tumori Journal ◽

10.1177/030089169508100511 ◽

1995 ◽

Vol 81 (5) ◽

pp. 359-363 ◽

Cited By ~ 7

Author(s):

Angeles Rovirosa ◽

Hugo Marsiglia ◽

Eric Lartigau ◽

Philippe Zimmermann ◽

Eric Chirat ◽

...

Keyword(s):

Dose Rate ◽

External Beam Radiotherapy ◽

High Dose Rate ◽

High Dose ◽

Effective Technique ◽

High Dose Rate Brachytherapy ◽

Iridium 192 ◽

Low Toxicity ◽

The Mean ◽

Karnofsky Index

Ten patients with advanced esophageal carcinoma were treated with endoluminal high-dose-rate brachytherapy at the Institut Gustave Roussy. Eight of them had recurrences after external beam radiotherapy. They were treated with a high-dose rate iridium-192 source. Five patients received 6 sessions of 4 Gy, 4 patients 3 sessions of 4 Gy, and 1 patient received 3 sessions of 8 Gy. The interval time between each session was 1 week. Seventy percent of patients improved their dysphagia, with 80% endoscopic tumor response. The Karnofsky index was improved in most of the patients. The mean survival was 4 months, and dysphagiafree survival was 2.5 months. Two patients had treatment toxicity but only a transitory WHO G1 esophagitis. Endoesophageal high-dose-rate curietherapy seems an effective technique in palliative treatments. We found low toxicity and an excellent tolerance to treatment in previously irradiated patients. The efficacy of the treatment is highly dependent on a precise tumor volume evaluation.

Download Full-text